CSF2 and neuroblastoma: Since many patients developed human anti-mouse antibodies (HAMAs) [119,121,122,123], an IgG1 humanized version of this antibody called Naxitamab was developed (Hu3F8) [124] and was approved for patients with refractory or relapsed high-risk neuroblastoma in combination with GM-CSF [125] after successful clinical trial results (NCT03363373, NCT01757626).